Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

ANG 111414-1095 A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients with Recurrent Brain Metastases Main Campus Phase 2Brain, Breast
BYLR 111414-770 Scalp Cooling Alopecia Prevention Trial (SCALP) Main Campus  Breast
CASE 1611212-1352 Association between Mammostrat score and pathologic response to neoadjuvant chemotherapy in Estrogen Receptor positive (ER+) early stage breast cancer Main Campus  Breast
CASE 411313-753 A Pilot Study for Evaluating the Neural Substrates of Cognitive impairments and movement-related fatigue in women undergoing adjuvant chemotherapy (CARES) Main Campus  Breast
CLDX 111414-506 A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over Expressing, Triple-Negative Breast Cancer (The “METRIC” Study) Main Campus  Breast
ECOG 2108CC13-074 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer Florida WestonStage 4Phase 3Breast
NFI 1114 14-1481 A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer Main Campus Phase 1, Phase 2Breast
NLG 111314-521 A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination with 1-methyl-D-tryptophan (indoximod) in Metastatic Breast Cancer Fairview, Florida Weston, Hillcrest, Main Campus Phase 2Breast
ROCH 1113061310C A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically In The Breast Or Axillary Lymph Nodes Following Preoperative Therapy Fairview, Hillcrest, Main Campus Phase 3Breast
RTOG 111913-551 Phase II Randomized study of whole brain radiotherapy in combination with concurrent lapatinib in patients with brain metastasis from HER2-Positive Breast cancer. A collaborative study of RTOG and KROG. Beachwood, Fairview, Hillcrest, Independence, Mansfield, North Coast Cancer, Parma, Strongsville, Wooster Phase 2Brain, Breast
SWOG 1007CC00111 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, Parma, South Pointe, Strongsville, Wooster Phase 3Breast
SWOG 120713-640 Phase III Randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk hormone receptor-positive and HER2/NEU negative breast cancer. E^3 Breast Cancer Study- Evaluating Everolimus with Endocrine Therapy Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster Phase 3Breast
TARGIT-US 14-599 Phase IV: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery Main Campus Phase 4Breast
ZNCA 1114 14-656 A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations Main Campus Phase 3Breast

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2015 Cleveland Clinic. All rights reserved.